Proteogenomic analysis of air-pollution-associated lung cancer 1

reveals prevention and therapeutic opportunities 2

Honglei Zhang^{1,*,#}, Chao Liu^{2,3,*}, Shuting Wang^{2,*}, Qing Wang^{4,*}, Xu 3

Feng¹, Huawei Jiang⁵, Yong Zhang^{6,#}, Xiaosan Su^{1,#} and Gaofeng $Li^{2,#}$ 4

¹Center for scientific research, Yunnan University of Chinese Medicine, Kunming, Yunnan, 5

6 650500, China;

- 7 ²Department of Thoracic Surgery II, Third Affiliated Hospital of Kunming Medical University,
- 8 Yunnan Cancer Hospital, Kunming 650106, China;
- ³Department of Nuclear Medicine, Third Affiliated Hospital of Kunming Medical University, 9
- 10 Yunnan Cancer Hospital, Kunming 650106, China;
- ⁴Department of Oncology, Qujing First People's Hospital, Qujing, 202150, China; 11
- 12 ⁵Department of Plastic Surgery, First Affiliated Hospital of Kunming Medical University,
- 13 Kunming 650032, China;
- 14 ⁶Department of Nephrology, Institutes for Systems Genetics, Frontiers Science Center for Disease-
- 15 Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
- ^{*}These authors contributed equally to this work. 16
- [#]Corresponding authors. Yong Zhang (nankai1989@foxmail.com), Xiaosan Su 17
- (suxs163@163.com); Gaofeng Li (ligaofeng@kmmu.edu.cn); Honglei Zhang 18
- 19 (hlzhang2014@163.com).
- 20
- 21
- 22
- 23
- 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

26 Abstract

Air pollution significantly impact lung cancer progression, but there is a 27 lack of a comprehensive molecular characterization of clinical samples 28 associated with air pollution. Here, we performed a proteogenomic 29 analysis of lung adenocarcinoma (LUAD) in 169 female never-smokers 30 from the Xuanwei area (XWLC cohort), where coal smoke is the primary 31 contributor to the high lung cancer incidence. Genomic mutation analysis 32 revealed XWLC as a distinct subtype of LUAD separate from cases 33 associated with smoking or endogenous factors. Mutational signature 34 analysis suggested that Benzo[a]pyrene (BaP) is the major risk factor in 35 XWLC. The BaP-induced mutation hotspot, EGFR-G719X, was present 36 in 20% of XWLC which endowed XWLC with elevated MAPK pathway 37 activations and worse outcomes compared to common EGFR mutations. 38 Multi-omics clustering of XWLC identified four clinically relevant 39 subtypes. These subgroups exhibited distinct features in biological 40 processes, genetic alterations, metabolism demands, immune landscape, 41 tumor microbiota composition and radiomic features. Finally, MAD1 and 42 TPRN were identified as novel potential therapeutic targets in XWLC. 43 Our study provides a valuable resource for researchers and clinicians to 44 explore prevention and treatment strategies for air-pollution-associated 45 lung cancers. 46

48 Introduction

Lung cancer is the leading cause of cancer deaths globally[1]. Though the 49 most common cause of lung cancer is tobacco smoking, studies estimate 50 that approximately 25% of lung cancers worldwide occur in individuals 51 who have never smoked[2]. Recently, lung cancer in never smokers 52 (LCINS) were molecular profiled and new genomic features were 53 revealed[3-9]. For now, further stratification of LCINS based on different 54 risk factors would be helpful to reveal the oncogenic mechanisms and 55 develop more targeted therapies. Air pollutants, which can directly affect 56 the pulmonary airway, play crucial roles in promoting lung 57 adenocarcinoma[10-12]. More than 20 environmental and occupational 58 agents are lung carcinogens[13, 14] and amount of studies have been 59 made to investigate molecular mechanisms in tumor progression of air 60 pollution chemicals or components using cell lines or mouse/rat 61 models[15-17]. However, a comprehensive molecular characterization of 62 clinical lung cancer samples associated with air pollution is still lacking. 63

The Xuanwei area has the highest rate of lung cancer in China, and 64 extensive research has established a strong link between lung cancer and 65 exposure to domestic coal smoke[18-23]. Specifically, etiologic link 66 between smoky coal burning and cancer was epidemiologically 67 established[18, 19] and association between household stove 68 improvement and lower risk of lung cancer was observed[23]. Moreover, 69

genomic evidence of lung carcinogenesis associated with coal smoke in 70 Xuanwei area, China was provided in our previous study[22]. Thus, lung 71 cancer in Xuanwei areas exemplifies the ideal disease to study 72 characteristics of lung cancers associated with air pollution. In recent 73 years, the molecular features of Xuanwei lung cancer have been gradually 74 revealed[24-26] [22]. A large sample size with multi-comic molecular 75 profiling is urgent needed to explicit the air pollution chemicals and 76 furthermore propose more targeted therapies. 77

To better understand the molecular mechanisms and heterogeneity of 78 XWLC and to advance precision medicine, we expanded the sample size 79 of our next-generation sequencing dataset to 169 sample size and 80 performed proteomic and phosphoproteomic profiling to 112 samples. 81 Furthermore, we integrated 107 radiomic features derived from X-ray 82 computed tomography (CT) scans to 115 samples to non-invasively 83 distinguish molecular subtypes. This allowed us to identify potential 84 major risk factor, distinguish the genomic features and establish clinically 85 relevant molecular subtypes. Our study provides an exceptional resource 86 for future biological, diagnostic, and drug discovery efforts in the study 87 of lung cancer related to air pollution. 88

89

90

92 **Results**

To investigate unique biological features of LUAD associated with air 93 pollution, three previous LUAD datasets related to different carcinogens 94 were used for comparison (Fig. 1a). CNLC is the subset of lung 95 adenocarcinoma from non-smoking patients in Chinese Human Proteome 96 Project (CNHPP project) [8] (n=77). TSLC is the subset of lung 97 adenocarcinoma from smoking female in TCGA-LUAD project [27] 98 (n=168). TNLC is the subset of lung adenocarcinoma from non-smoking 99 female in TCGA-LUAD project[27] (n=102). The clinicopathological 100 characteristics of patients from CNLC, TSLC and TNLC cohorts were 101 supplied in Supplementary Table 1a and 1b. 102

103 **Proteogenomic landscape in Xuanwei lung cancer (XWLC)**

The present study prospectively collected primary samples of lung 104 adenocarcinoma (LUAD) from 169 never-smoking women from the 105 Xuanwei area in China (Supplementary Table 1c). The XWLC cohort had 106 a median age of 56 years (Fig. 1b), and the majority of tissue samples 107 were in the early stages of the disease (145 were stage I/II, and 24 were 108 stage III/IV, Fig. 1c). A total of 135, 136, 102 and 102 tumor samples 109 were profiled with whole-exome sequencing (WES), RNA-seq, label-free 110 protein quantification, and label-free phosphorylation quantification, 111 respectively (Fig.1d-e and Extended Fig.1a and 1b). Analysis of the WES 112 data from the paired tumor and normal tissue samples revealed 37,149 113

somatic mutations, including 1,797 InDels, 32,972 missense mutations, 114 2,345 nonsense mutations, and 35 nonstop mutations (Supplementary 115 2). number analysis showed 140,396 Table Copy gene-level 116 amplifications and 67,605 deletions across 40 cytobands (Supplementary 117 Table 3). The mRNA-seq data characterized the transcription profiles of 118 19,182 genes (Supplementary Table 4). The label-free global proteomics 119 identified 9,152 proteins (encoded by 6,864 genes) with an average of 120 6.457 proteins per sample (Supplementary Table 5). The label-free 121 phosphoproteomics identified 24,990 highly reliable phosphosites from 122 5,832 genes with an average of 10,478 phosphosites per sample 123 (Supplementary Table 6). The quality and reproducibility of the mass 124 spectrometry data were maintained throughout the study (Extended Data 125 Fig. 1c-e). 126

The air pollutant Benzo[a]pyrene (BaP) primarily contributes to the mutation landscape of XWLC

To infer the primary risk factor responsible for the progression of XWLC, we used SomaticSignatures[28] to identify mutational signatures from single nucleotide variants. Mutational signatures were identified in each cohort and a cosine similarity analysis was performed against mutational signatures in COSMIC mutational signatures[29, 30] and environmental agents mutational signatures[31] allowing for inference of the underlying causes (Fig. 1f-i and Extended Fig. 2). Generally, exposure tobacco

smoking carcinogens (COSMIC signature) and chemicals such as BaP 136 (environmental agent signature) were identified as the most significant 137 contributing factors in both the XWLC and TSLC cohorts (Fig. 1f and 138 1g). In contrast, defective DNA mismatch repair and endogenous 139 mutational processes initiated by spontaneous deamination of 5-140 methycytosine were inferred as the major causes in the TNLC and CNLC 141 cohorts (Fig. 1h and 1i). Therefore, the XWLC and TSLC cohorts are 142 more explicitly influenced by environmental carcinogens, while the 143 TNLC and CNLC cohorts may be more affected by age or endogenous 144 BaP, a representative compound of polycyclic aromatic risk factors. 145 hydrocarbons (PAHs), is found in both cigarette smoke and coal smoke 146 and is recognized as a major environmental risk factor for lung 147 cancer[32-34]. Upon metabolism, BaP forms the carcinogenic metabolite 148 7β , 8α -dihydroxy- 9α , 10α -epoxy-7, 8, 9, 10-tetrahydrobenzo[a]pyrene 149

(BPDE), which creates DNA adducts leading to mutations and malignant 150 transformations. This process involves two key regulators: CYP1A1 and 151 AhR. CYP1A1 plays a crucial role in BaP epoxidation at the 7,8 positions, 152 which is the most critical step in BPDE formation[35]. AhR is a ligand-153 activated transcription factor that responds to various chemicals, 154 chemical carcinogens, and is including activated by BaP[36]. 155 Accordingly, our results demonstrated significantly higher expression of 156 CYP1A1 and AhR in tumor samples compared to normal samples (Fig. 1j 157

and 1k). To validate the association between BaP and the elevated 158 incidence of lung cancer in the Xuanwei area, we assessed the serum 159 BPDE levels in individuals residing in this region (Methods). Our 160 findings revealed that the serum BPDE content in individuals from the 161 Xuanwei area averaged around 0.85 nm/ml, and there was no difference 162 between younger and older cases (Fig. 11 and Supplementary Table 7). 163 Furthermore, we treated hiPSC (human induced pluripotent stem cell 164 (hiPSC) with BaP in vitro and found that sites such as Y1173 and Y1068 165 of EGFR were more phosphorylated in BaP treated cells whereas the total 166 abundance of EGFR showed no significant differences (Fig. 1m). All 167 these results provided further evidence for the involvement of BaP and its 168 metabolite in the development of lung cancer. 169

Though coal-smoke related lung cancer (XWLC cohort) and 170 cigarette-smoke related lung cancer (TSLC cohort) showed similar 171 environmental carcinogens, we found that downstream pathway 172 activation and therapeutic targeted potential showed distinctive features. 173 Firstly, the correlation of genomic mutations between XWLC and TSLC 174 was found to be low (Fig. 2a). Secondly, there was a remarkable 175 difference in the fraction of samples affected by pathway mutations 176 between two cohorts (Fig. 2b). Notably, the TSLC cohort exhibited a 177 higher fraction of samples affected by oncogenic pathways comparing to 178 XWLC cohort. Thirdly, mutation frequencies, such as EGFR, TP53, 179

RBM10, and KRAS (Fig. 2c), as well as the distribution of amino acid 180 changes in EGFR and TP53, showed significant differences between the 181 XWLC and other cohorts (Fig. 2d). Specifically, the XWLC cohort 182 exhibited a higher mutation rate in G719C/A/D/S and E746 A750del 183 within the EGFR gene compared to the other three cohorts. For the TP53 184 gene, frame shift mutations including D9Gfs*3 (n=1), S15Ifs*28 (n=1), 185 D22Efs*61 (n=1), and V34Wfs*49 (n=2) were exclusively detected in the 186 XWLC cohort, whereas tetramer domain mutations were only found in 187 the other three cohorts (Fig. 2d). Finally, there was a noticeable disparity 188 in the percentage of samples with actionable targets among the cohorts. 189 (Fig. 2e). Actionable targets in XWLC cohort were mainly focus on 190 EGFR mutations including pG719S, pG719C, pG719A, pL858R, 191 p.E746 A750del whereas TSLC cohort had more actionable targets in 192 CHEK2 p.K373E, KRAS p.G12V/D/C/A (Fig. 2e). 193

Taken together, we found that the XWLC and TSLC cohorts, which 194 are smoke-related lung adenoma groups, demonstrated distinct etiology 195 compared to the TNLC and CNLC cohorts which may be influenced by 196 endogenous risk factors to a greater extent. The blood serum assay 197 provided support for BaP as a promising risk factor specifically in the 198 XWLC cohort. Additionally, significant disparities were observed 199 between XWLC and TSLC in terms of downstream pathway activations 200 and specific oncogene loci. Consequently, we conclude that air pollution-201

associated lung cancer represents a distinct subtype within LUAD.

203 The EGFR-G719X mutation, which is a hotspot associated with BaP

204 **exposure, possesses distinctive biological features**

Notably, the XWLC cohort displayed a distinguishable mutation pattern 205 in specific EGFR mutation sites compared to the other cohorts (Fig.3a 206 and Fig.2d). In particular, the G719C/A/D/S (G719X) mutation was the 207 most prevalent EGFR mutation in the XWLC cohort (20%), while it was 208 rarely found in the other three cohorts (CNLC: 1.9%; TSLC: 1.9%; 209 TNLC: 0) (Fig. 3b). Notably, we found it was a hot spot associated with 210 BaP exposure (Fig. 3c and 3d). Specifically, GGC is the 719 codon, the 211 first G can be converted to T (pG719C, n=13) or A (pG719S, n=5), the 212 second G can be converted to A (pG719D, n=1) or C (pG719C, n=8). 213 Thus, pG719C was the most detected mutation type (Fig. 3c). G>T/C>A 214 transversion can be induced by several compounds such as BaP or 215 dibenz(a,h)anthracene (DBA), unlike other compounds, the tallest peak 216 induced by BaP occurs at GpGpG, reflecting how their DNA adducts are 217 formed principally at N²-guanine[31]. Our result showed that the most 218 frequently detected pG719C AAchange was correspond to 219 GGGC>GTGG transversion (Fig. 3d). Thus, pG719C is a hot spot 220 associated with BaP exposure. 221

We conducted further investigations into the biological characteristics of samples carrying the G719X mutations. Notably, we observed a

moderate to high expression of MAPK signaling components, MAP2K2 224 (MEK), and MAPK3 (ERK1), in tumors harboring the EGFR-G719X 225 mutation compared to other EGFR statuses (Fig. 3e-3h). Utilizing 226 hallmark capability analysis and RNA-seq-based estimation of immune 227 cell infiltration, we found that tumors with G719X mutations exhibited 228 similarities to those with L858R mutations (Extended Data Fig. 3a-b). 229 However, patients with G719X mutations were notably younger than 230 those with L858R mutations, indicating a higher occurrence rate of 231 G719X in younger female patients (Fig. 3i). Analysis of overall survival 232 and progression-free interval (PFI) revealed that patients with the G719X 233 mutation had worse outcomes compared to other EGFR mutation 234 subtypes (Fig. 3j and 3k). Furthermore, there were no significant 235 differences in mutation burden or the number of neoantigens between 236 tumors with G719X mutations and tumors with other EGFR mutation 237 statuses (Extended Data Fig. 3c). 238

To explore the heterogeneity of signaling pathways activated by different *EGFR* mutation statuses, we conducted Kinase-Substrate Enrichment Analysis (KSEA) [37, 38] based on the XWLC phosphoproteomics dataset. Our analysis of the phosphoproteome across various *EGFR* mutation types revealed distinct activation patterns of kinases. Specifically, the G719X mutation was associated with the activation of PRKCZ, CDK2, AURKB, CSNK1A1, CDK4, and HIPK2.

The L858R mutation showed activation of PRKCZ, MAPK7, MAPK12, 246 HIPK2, and CSNK2A1. The Exon19del mutation exhibited activation of 247 CHUK, TTK, PRKCZ, PLK1, NEK2, MAP2K2, CDK2, PRKDC, and 248 MAP2K6. Other EGFR mutations were associated with the activation of 249 AURKB, NEK2, TTK, PLK1, PRKACB, and PRKACG. EGFR-WT 250 mutations showed activation of CSNK1E, PRKCZ, AURKB, CDK2, 251 AURKC, CDK1, CSNK1A1, PRKDC, and CSNK2A1 (Fig. 31). In 252 Extended Data Fig. 3d, we provide a list of FDA-approved drugs that 253 target the activated kinases in tumors harboring the G719X mutation. 254 Currently, afatinib is widely regarded as a first-line therapy for patients 255 with the G719X mutation[39-42]. However, reports indicate that 80% of 256 patients with this mutation may develop resistance to afatinib, even in the 257 absence of T790M[43], underscoring the need for a deeper understanding 258 of the downstream pathways associated with the G719X mutation. 259 Therefore, a promising approach to overcome resistance in tumors with 260 this mutation could involve combining afatinib, which targets activated 261 EGFR, with FDA-approved drugs that specifically target the activated 262 kinases associated with G719X. 263

264 Clinically relevant Subtyping in XWLC

To uncover the inherent subgroups within air-pollution-associated tumors, we employed unsupervised Consensus Clustering[44] on integrated RNA, protein, and phosphoprotein profiles of XWLC tumor samples. This

analysis led to the identification of four distinct intrinsic clusters, denoted 268 as MC-I, II, III, and IV (Fig. 4a, Extended Data Fig. 4a and Methods). 269 Further survival analysis demonstrated that patients belonging to the MC-270 IV group exhibited the poorest overall survival compared to the other 271 three subgroups, thus indicating the prognostic potential of multi-omic 272 clustering (Fig. 4b). Notably, there were no significant differences in 273 clinical features such as age and stage observed among the four 274 subgroups (Fig. 4a). Since BaP has the potential to induce the expression 275 of CYP1A1 and AhR, we utilized the expression levels of CYP1A1 and 276 AhR as indicators of BaP activity. Consequently, we compared the 277 expression levels of CYP1A1 and AhR among the four subtypes to 278 identify the tumor type most strongly associated with air pollution. Our 279 findings revealed that the MC-II subtype exhibited higher expression of 280 CYP1A1 (Fig. 4c) and moderately elevated expression level of AhR 281 compared to the other three subtypes (Fig. 4d) Moreover, the MC-II 282 possessed more G719X mutations (MC-1:0.39, MC-II:0.42, MC-III: 0.20, 283 MC-IV: 0.08). These results collectively suggest a stronger association 284 between the MC-II subtype and BaP exposure. Notably, there was a 285 significant correlation between CYP1A1 and EGFR expression (Fig. 4e), 286 with EGFR being more highly expressed in the MC-II subtype (Fig. 4f). 287 These results indicated that MC-II was more associated with air-288 pollution. 289

Through Kinase Substrate Enrichment Analysis (KSEA) of the 290 phosphoproteome in tumor samples compared to normal adjacent tissues 291 (NATs), we identified specific kinase activations within the four 292 subgroups. In MC-I samples, kinase activations included PRKDC, 293 PRKCZ, CSNK1A1, NEK2, GSK3A, and ROCK1. MC-II samples 294 showed activations of CDK2, CDK1, AURKA, TTK, CDK6, and CHUK. 295 MC-III samples exhibited activations of AKT1, AKT3, RPS6KB1, 296 CSNK2A1, and PAK2. Finally, CDK2 and ROCK1 were activated in 297 MC-IV samples (Fig. 4g). Particularly noteworthy is the enrichment of 298 CDK1/2/6 kinases, which regulate cell cycle checkpoints, in the MC-II 299 subtype, indicating its high proliferation capabilities. These findings 300 imply that distinct kinase pathways are activated within each subgroup, 301 suggesting the presence of specific therapeutic targets for each subgroup. 302 Consequently, we proceeded to explore therapeutic strategies for each 303 subgroup as outlined below: 304

The MC-IV subtype exhibited the poorest overall survival compared to the other three subtypes (Fig. 4b). Given the crucial role of epithelialmesenchymal transition (EMT) in malignant progression, our first evaluation focused on the EMT process across the four subtypes. We observed higher expression levels of mesenchymal markers such as *VIM*, *FN1*, *TWIST2*, *SNAI2*, *ZEB1*, *ZEB2*, and others in the MC-IV subtype (Fig. 5a). To comprehensively assess the EMT capability of the MC-IV

subtype, we calculated EMT scores using the ssGSEA enrichment 312 method based on protein levels and GSEA hallmark gene set 313 (M5930)[45]. The results confirmed the elevated EMT capability of the 314 MC-IV subtype at the protein level (Fig. 5b). Furthermore, Fibronectin 315 (FN1), an EMT marker that promotes the dissociation, migration, and 316 invasion of epithelial cells, was found to be highly expressed in the MC-317 IV subtype at the protein level (Fig. 5c). Additionally, β -Catenin, a key 318 regulator in initiating EMT, was highly expressed in the MC-IV subtype 319 at the protein level (Fig. 5d). Collectively, our findings demonstrate that 320 the MC-IV subtype possesses an enhanced EMT capability, which may 321 contribute to the high malignancy observed in this subtype. 322

The **MC-II** subtype demonstrated the second-worst outcome and was 323 found to be more strongly associated with air pollution (Fig. 4). This 324 subtype exhibited dysregulation of cell cycle processes, including cell 325 division, glycolysis, and cell cycle biological processes (Fig. 4a). The 326 KSEA analysis revealed that the CDK1 and CDK2 pathways, which are 327 closely linked to cell cycle regulation, were predominantly activated in 328 the MC-II subtype (Fig. 5e). Consistently, we observed higher expression 329 levels of CDK1 and CDK2 at both the protein and phosphoprotein levels 330 in the MC-II subtype, indicating specific elevation of the G2M phase in 331 the cell cycle (Fig. 5e). The cell cycle and glycolysis processes are tightly 332 coordinated, allowing cells to synchronize their metabolic state and 333

energy requirements with cell cycle progression to ensure proper cell 334 growth and division[46-48]. In line with this, we found that key enzymes 335 involved in glycolysis regulation, such as Hexokinase 1 (HK1), 336 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and 337 Glyceraldehyde-3-phosphate dehydrogenase-like protein (GPL), were 338 highly expressed in the MC-II subtype (Fig. 5f). Additionally, the MC-II 339 subtype was enriched with EGFR mutations (MC-II vs. others: 18/24 vs. 340 51/110; Fisher's exact p = 0.013) and TP53 mutations (MC-II vs. others: 341 14/24 vs. 35/110; Fisher's exact p = 0.019), consistent with the 342 characteristic loss of control over cell proliferation. In summary, the MC-343 II subtype exhibited dysregulated cell cycle processes accompanied by an 344 elevated glycolysis capability, indicating a distinct metabolic and 345 proliferative phenotype. 346

The MC-I subtype exhibited enrichment in various biological 347 processes including angiogenesis, the cAMP signaling pathway. 348 complement and coagulation cascades, PDL1 expression, the PD-1 349 checkpoint pathway, leukocyte transendothelial migration, and actin 350 cytoskeleton processes (Fig. 4a). In-depth exploration of key components 351 involved in angiogenesis revealed that vascular endothelial growth factor 352 A (VEGFA), a growth factor crucial for both physiological and 353 pathological angiogenesis, was highly expressed in the MC-I subtype (Fig. 354 5g). Additionally, phosphorylation of vascular endothelial growth factor 355

receptor 1 (VEGFR1), a receptor tyrosine kinase essential for 356 angiogenesis and vasculogenesis, was also highly expressed in the MC-I 357 subtype (Fig. 5h). The angiogenesis scores, calculated using the ssGSEA 358 method based on protein levels and the hallmark gene set (M5944), were 359 relatively high in the MC-I and MC-IV subtypes (Fig. 5i). Furthermore, 360 the relationship between the Notch signaling pathway and angiogenesis is 361 well-established[49]. Notch signaling plays a role in multiple aspects of 362 angiogenesis, including endothelial cell sprouting, vessel branching, and 363 vessel maturation [50, 51]. In the MC-I subtype, the expression of Notch 364 receptors (Notch1-4) and ligands (DLL1, DLL4, JAG1, and JAG2) was 365 highly elevated, indicating increased activation of Notch signaling (Fig. 366 5j). KEGG pathview analysis demonstrated that key regulators of the 367 VEGF signaling pathway were highly expressed in the MC-I subtype 368 (Extended Fig.5a). Therefore, manipulating Notch signaling could 369 potentially serve as a strategy to regulate angiogenesis and control 370 pathological angiogenesis in the MC-I subtype. 371

The **MC-III** subtype is characterized by the upregulation of various 372 metabolic processes, including oxidative phosphorylation, peroxisome 373 function, adipogenesis, fatty acid metabolism, and xenobiotic 374 metabolism-related processes (Fig. 5k). Additionally, we conducted 375 further investigations into the immune features across the subtypes. 376 Interestingly, we observed higher expression of genes associated with 377

PD-1 signaling (GSEA, SYSTEMATIC_NAME M18810) in the MC-III 378 subtype (Fig. 51). Since PD-1 is primarily expressed on the surface of 379 certain immune cells, particularly activated T cells, we inferred the 380 immune cell infiltration using the ssGSEA method based on immune cell-381 specific gene sets. We found that activated CD8+ T cells exhibited higher 382 infiltration levels in the MC-III subtype compared to the other three 383 subtypes (Fig. 5m and Supplementary Table 8), which may explain the 384 elevated PD-1 signaling in the MC-III subtype. Furthermore, we 385 examined the expression of receptor-ligand pairs involved in both anti-386 tumor and pro-tumor lymphocyte recruitment. Remarkably, the MC-III 387 subtype exhibited specific high expression of anti-tumor lymphocyte 388 receptors and ligands, while the expression of pro-tumor lymphocyte 389 receptors and ligands was relatively lower (Fig. 5n). In general, the MC-I 390 subtype showed the reverse expression trend in terms of anti-tumor and 391 pro-tumor receptor-ligand pairs (Fig. 5n). 392

In conclusion, our classification of lung adenocarcinoma associated with air pollution resulted in the identification of four subtypes, each exhibiting distinct biological pathway activation and immune features. The MC-I subtype demonstrated elevated angiogenesis processes, while the MC-II subtype showed a high capacity for cell division and glycolysis. The MC-III subtype exhibited a notable infiltration of CD8+ cells, and the MC-IV subtype was characterized by high EMT capability, which

may contribute to its poor outcome. These findings have significant
implications for the development of precision treatments for XWLC
(Extended Fig.5b).

403 Tumor microbiota composition and radiomic features across 404 subtypes

Host-bacterial immune interactions profoundly influence tumorigenesis, 405 cancer progression, and response to therapy[52-54]. Thus, we further 406 generated species-level resolution data allowing the identification of 407 specific bacteria across subgroups. Firstly, we extracted and mapped 408 high-quality reads of bacterial origin from RNA-Seq datasets across 409 normal and four tumor subgroups of the XWLC cohort using PathSeq[55] 410 while carefully mitigating the influences of microbial contamination 411 (Supplementary Table 9 and Methods). We found that the subgroups 412 showed distinct bacterial abundances (Fig. 6a). Principal coordinate 413 analysis (PCoA)[56] of UniFrac distances of species abundances across 414 subgroups revealed that the first PCoA axis generally captured 415 differences between tumor and adjacent normal tissues, while the second 416 axis mainly captured the differences between the MC-IV subgroup and 417 the other three subgroups (Fig. 6b). Thus, the MC-IV subgroup showed 418 distinguishable bacterial composition compared to the other three 419 subgroups. We further identified 16 bacterial species that were enriched 420 in the MC-IV subgroup, mainly belonging to the Pseudomonas, 421

422 Stenotrophomonas, Acidovorax, Rheinheimera, Brevundimonas, 423 Sphingomonas, and Methyloversatilis genera (Fig. 6c). Among them, 424 Acidovorax and Brevundimonas have been identified within lung tumor 425 sections[57]. Further investigation is warranted to determine whether and 426 how the unique microbiota composition of MC-IV contributes to its 427 malignancy.

Furthermore, we built a noninvasive method to distinguish MC 428 subtypes with radiomics which entails the extensive quantification of 429 tumor phenotypes by utilizing numerous quantitative image features. In 430 the initial step, we defined 107 quantitative image features that describe 431 various characteristics of tumor phenotypes, including tumor image 432 intensity, size, shape, and texture. These features were derived from X-433 ray computed tomography (CT) scans of 155 patients with XWLC 434 (Methods). The baseline characteristics of this cohort can be found in 435 Supplementary Table 10. Firstly, all features were compared among the 436 four subtypes, and notably, eight features showed significant differences 437 between the MC-II subtype and the other three subtypes (Fig. 6d), 438 suggesting a denser image in the MC-II subtype. We further established a 439 signature using a multivariate linear regression model with five image 440 features to distinguish MC-II from the other three subgroups (Extended 441 Fig.6). The performance of the five-feature radiomic signature was 442 validated using the AUC value, which is a generation of the area under 443

the ROC curve. The radiomic signature had an AUC value of 0.94 in the
training set and 0.83 in the validation set (Fig. 6e). The confusion matrix
revealed an overall accuracy of 0.875 for sample classification using the
signature, indicating proficient performance. However, it exhibited
suboptimal performance in terms of false-negative classification (Fig. 6f).
Taken together, we found that MC-II showed a dense image phenotype,
which can be noninvasively distinguished using radiomic features.

451 Identification of novel targets based on mutation-informed protein-

452 protein interface (PPI) analysis

The integration of genomics and interactomics has enabled the discovery 453 of functional and biological consequences of disease mutations[58, 59]. 454 To explore novel targets with the concept, we created PPI networks with 455 structural resolution using missense mutations from the XWLC, CNLC, 456 TSLC, and TNLC cohorts (Fig.7a and Methods). OncoPPIs, defined as a 457 significant enrichment of interface mutations in either of the two protein-458 binding partners across individuals, were identified in each cohort and 459 were provided in Supplementary Tables 11. The OncoPPIs from the four 460 cohorts named XWLC oncoPPIs, CNLC oncoPPIs, are 461 TSLC oncoPPIs, and TNLC_oncoPPIs, respectively (Fig. 7b and 462 Extended Fig. 7a-c). Initially, the nodes from these four OncoPPIs were 463 subjected to biological process enrichment analysis (Extended Fig. 7d). 464 The analysis revealed that biological processes such as regulation of 465

466 mitotic cell cycle, TGF-beta signaling pathway, and immune system were 467 predominantly enriched in the genes related to OncoPPIs. Moreover, the 468 processes disrupted by interface mutations showed a relatively higher 469 similarity between the XWLC and TSLC cohorts (Extended Fig. 7d) 470 suggesting convergent targets or pathways affected by smoke-induced 471 mutations.

To refine the novel targets from XWLC oncoPPs, we performed 472 molecular dynamics simulations to predict the binding affinity change by 473 the interface-located mutations (Methods). Mitotic Arrest Deficient 1 474 Like 1 (MAD1), a crucial component of the mitotic spindle-assembly 475 checkpoint[60, 61], forms a tight core complex with MAD2, facilitating 476 the binding of MAD2 to CDC20[62], which plays a critical role in sister 477 chromatid separation during the metaphase-anaphase transition[63]. 478 Specifically, MAD1 Arg558His has been identified as a susceptibility 479 factor for lung cancer[64] and colorectal cancer[65]. Here, we found that 480 MAD1 allele carrying a p.Arg558His substitution may disrupt the 481 interaction between MAD1 and MAD2 (Fig.7b-c). To assess this, we 482 performed molecular dynamics simulations and found that the binding 483 affinity between Arg558His MAD1 and MAD2 was -195.091 kJ/mol and 484 that of wild type was -442.712 kJ/mol (Fig.7c). Furthermore, on a per-485 residue basis, the predicted binding affinity ($\Delta\Delta G$) of Arg558His 486 (Extended Fig.7e) was projected to increase by 118.319 kJ/mol relative to 487

the wild type (Extended Fig.7f), indicating that the substitution of Arg558His in MAD1 perturbs the binding affinity. Thus, our findings suggest that the MAD1 Arg558His attributed to lung cancer progression by disrupting of the interaction between MAD1 and MAD2, which showed potential to be explored as a target.

Notably, we identified TPRN as a novel significantly mutated gene in 493 the XWLC cohort (Extended Fig.7g and 7h) whose status was also 494 associated with patients' outcomes (Fig.7e). Previous studies have 495 reported that TPRN interacts with PPP1CA[66]. Thus, we assessed the 496 binding affinity of the TPRN-PPP1CA complex affected by the mutant 497 variant His550Gln. Our result showed that the binding affinities of the 498 complex were -694.372 kJ/mol and -877.570 kJ/mol in mutant and WT 499 cases, respectively (Fig.7d). On a per-residue basis, the predicted $\Delta\Delta G$ of 500 His550Gln compared to the wild type exhibited an increase of 96.774 501 kJ/mol (Extended Fig. 7i-j). All these results indicated that TPRN 502 His550Gln increase the binding affinity of the TPRN-PPP1CA complex. 503 To investigate the effect of TPRN His550Gln mutation on tumor 504 progression, we examined proliferation and migration capabilities in both 505 A549 and H1299 lung adenocarcinoma cell lines. CCK-8 assay showed 506 significantly enhanced cell growth after transfection of TPRN mutant 507 allele in both A549 (Fig.7f) and H1299 cells (Extended Fig. 8a). 508 Moreover, wound-healing assay showed that TPRN mutant cell had 509

achieved enhanced migration capacity (Fig.7g-h and Extended Fig. 8b-c).
Finally, more cell clones in TPRN His550Gln mutation cells were
observed in both TPRN-mutant A549 and H1299 cells (Fig.7i). All these
results supported that TPRN His550Gln could be explored as a target in
XWLC.

Taken together, our integrated analysis of oncoPPIs and molecular dynamics simulations showed potential to explore novel therapeutic vulnerabilities.

518 **Discussion**

In this study, we conducted proteogenomic and characterized air-519 pollution-related lung cancers. We found that Benzo[a]pyrene (BaP) 520 influenced the mutation landscape, particularly the EGFR-G719X hotspot 521 found in 20% of cases. This mutation correlated with elevated MAPK 522 pathway activation, worse clinical outcomes, and younger patients. Multi-523 omics clustering identified four subtypes with unique biological pathways 524 and immune cell patterns. Moreover, our analysis of protein-protein 525 interfaces unveiled novel therapeutic targets. These findings have 526 significant implications for preventing and developing precise treatments 527 for air-pollution-associated lung cancers. 528

Previously considered uncommon, the EGFR-G719X mutation was detected in only 1-2% of CNLC or TCGA-LUAD cohort samples. Limited knowledge exists from G719X, mostly based on isolated case

reports or small series studies[67-71]. In vitro experiments using G719X 532 mutant cell lines and patient-derived xenografts (PDX) demonstrated that 533 osimertinib effectively inhibits signaling pathways and cellular growth, 534 leading to sustained tumor growth inhibition[72]. However, in silico 535 protein structure analysis suggests that G719 alterations may confer 536 osimertinib resistance due to reduced EGFR binding[73]. Presently, 537 afatinib is proposed as the first-line therapy for G719X mutation 538 patients[39-42]. Unfortunately, 80% of G719X patients develop acquired 539 resistance to afatinib without detecting the T790M mutation40. Hence, 540 further mechanistic studies are warranted for G719X. Our study reveals 541 that the G719X mutation is prevalent in the XWLC cohort, significantly 542 impacting treatment selection. Additionally, the large number of G719X 543 samples allowed us to uncover variations in biology and pathway 544 activation, which may facilitate the development of more precise targeted 545 therapies for these patients. 546

There is substantial evidence linking lung cancer in the Xuanwei area to coal smoke[18, 19, 21, 22, 74, 75]. In addition, we conducted a rat model study that demonstrated the induction of lung cancer by local coal smoke exposure[22]. However, the specific chemical compound in coal smoke responsible for causing lung cancer remains largely unknown. Previous research has mainly focused on studying indoor concentrations of airborne particles and BaP[18, 19, 21, 23, 76]. For instance, studies

have shown an association between the concentration of BaP and lung 554 cancer rates across counties[18]. Moreover, improvements in household 555 stoves have led to reduced exposure to benzopyrene and particulate 556 matter, benefiting people's health[23, 76]. However, these studies 557 primarily relied on epidemiological data, which may be influenced by 558 confounding factors. In our study, we used clinical samples and linked the 559 mutational signatures of XWLC to the chemical compound BaP, which 560 advanced the etiology and mechanism of air-pollution-induced lung 561 cancer. 562

In summary, our proteogenomic analysis of clinical tumor samples provides insights into air-pollution-associated lung cancers, especially those induced by coal smoke and offers an opportunity to expedite the translation of basic research to more precise diagnosis and treatment in the clinic.

568 **Declarations**

569 **Ethical Approval**

The study protocol was reviewed and approved by the ethical committees of Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University (KYCS2022067) and conformed to the ethical standards for medical research involving human subjects, as laid out in the 1964 Declaration of Helsinki and its later amendments.

575 **Consent to participate**

576 Participants provided written informed consent prior to taking part in the577 study.

578 **Consent for publication**

579 Written informed consent was obtained from the patient and the ethical

committees of Yunnan Cancer Hospital & The Third Affiliated Hospital

of Kunning Medical University for publication of this study.

582 **Competing interests**

583 The authors declare no competing interests.

584 Authors' contributions

Honglei Zhang, Gaofeng Li, Xiaosan Su and Yong Zhang conceived the
study. Honglei Zhang, Chao Liu, Qing Wang and Shuting Wang
performed data analysis. Honglei Zhang wrote the manuscript. Xu Feng,
Heng Li, Zhiyong Deng, Huawei Jiang, Yunyan He, Chao Luo, Rou Qian,
Minjun Zhou, Zhi Li, Li Xiao, Yong Zhang interpreted the data analysis
and drafted the manuscript and critically revised the manuscript. All
authors critically revised and gave final approval of the manuscript.

592 Funding

This work was supported by National Natural Science Foundation (Nos. 82273501, 81960322, 82160343, 82060519, 81860171); Yunnan young and middle-aged academic and technical leaders Reserve Talents Project (No. 202005AC160048); Yunnan basic research program (Nos.202101AZ070001-002, 202001AY070001-277, 2019FE001(-236));

598 Medical Reserve Personnel Training Program of Yunnan Provincial

- Health Commission(No. H-2018097); "Famous Doctor" Special Project
- of Ten Thousand People Plan of Yunnan Province(Nos.CZ0096, YNWR-
- 601 MY-2020-095); Medical Leading Talents Training Program of Yunnan
- 602 Provincial Health Commission (No.L-2019028).

603 Acknowledgements

We thank Novogene Co., Ltd. and Beijing Qinglian Biotech Co., Ltd. for the analysis of mass spectrometric data.

606 Availability of data and materials

Raw sequencing data have been deposited in the Genome Sequence Archive for Human (GSA-Human, https://ngdc.cncb.ac.cn/gsa-human/) under accession codes HRA000124, HRA001481 and HRA001482. Proteomics and phosphoproteomics data have been deposited in the Open Archive for Miscellaneous Data (OMIX, https://ngdc.cncb.ac.cn/omix/) under accession codes OMIX001292. The raw lung CT images used in this paper are available from OMIX under accession codes OMIX002491.

614

616 **References**

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics
 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
 countries. CA Cancer J Clin 2018, 68:394-424.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin
 2005, 55:74-108.
- 622 3. Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, Alvarez JJS, Lu B, Lim JQ,
 623 Takano A, et al: Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet
 624 2020, 52:177-186.
- Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R,
 Fulton L, Wallis J, et al: Genomic landscape of non-small cell lung cancer in smokers and
 never-smokers. *Cell* 2012, 150:1121-1134.
- 628 5. Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, Chen HW, Chang GC,
 629 Chang YL, Wu CT, et al: Proteogenomics of Non-smoking Lung Cancer in East Asia
 630 Delineates Molecular Signatures of Pathogenesis and Progression. Cell 2020, 182:226631 244.e217.
- 6. Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, Lokanga R, Moye AL, Rosenbaum J,
 633 Gonzalez-Perez A, Martinez-Jimenez F, et al: Genomic and evolutionary classification of
 634 lung cancer in never smokers. *Nat Genet* 2021, 53:1348-1359.
- 635 7. Zhang XC, Wang J, Shao GG, Wang Q, Qu X, Wang B, Moy C, Fan Y, Albertyn Z, Huang X,
 636 et al: Comprehensive genomic and immunological characterization of Chinese non-small
 637 cell lung cancer patients. *Nat Commun* 2019, 10:1772.
- 8. Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, et al:
 Integrative Proteomic Characterization of Human Lung Adenocarcinoma. *Cell* 2020,
 182:245-261.e217.
- 641 9. Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, Li Y,
 642 Liang WW, Reva B, et al: Proteogenomic Characterization Reveals Therapeutic
 643 Vulnerabilities in Lung Adenocarcinoma. *Cell* 2020, 182:200-225 e235.
- Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan FC, Marongiu F, Evans EJ,
 Jr., Moore DA, et al: Lung adenocarcinoma promotion by air pollutants. *Nature* 2023,
 646 616:159-167.
- Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, 3rd, Prada D,
 Samet J, Thurston G, Cohen A: Outdoor air pollution and cancer: An overview of the
 current evidence and public health recommendations. CA Cancer J Clin 2020.
- Fajersztajn L, Veras M, Barrozo LV, Saldiva P: Air pollution: a potentially modifiable risk
 factor for lung cancer. *Nat Rev Cancer* 2013, 13:674-678.
- 652 13. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V,
 653 Benbrahim-Tallaa L, Guha N, Freeman C, et al: Preventable exposures associated with
 654 human cancers. J Natl Cancer Inst 2011, 103:1827-1839.
- Humans IWGotEoCRt: Some non-heterocyclic polycyclic aromatic hydrocarbons and
 some related exposures. *LARC Monogr Eval Carcinog Risks Hum* 2010, 92:1-853.
- 657 15. Shi Q, Godschalk RWL, van Schooten FJ: Inflammation and the chemical carcinogen
 658 benzo[a]pyrene: Partners in crime. *Mutat Res Rev Mutat Res* 2017, 774:12-24.

659	16.	Saravanakumar K, Sivasantosh S, Sathiyaseelan A, Sankaranarayanan A, Naveen KV, Zhang
660		X, Jamla M, Vijayasarathy S, Vishnu Priya V, MubarakAli D, Wang MH: Impact of
661		benzo[a]pyrene with other pollutants induce the molecular alternation in the biological
662		system: Existence, detection, and remediation methods. Environ Pollut 2022, 304:119207.

- 663 17. Abd El-Fattah EE, Abdelhamid AM: Benzo[a]pyrene immunogenetics and immune 664 archetype reprogramming of lung. Toxicology 2021, 463:152994.
- 665 Mumford JL, He XZ, Chapman RS, Cao SR, Harris DB, Li XM, Xian YL, Jiang WZ, Xu CW, 18. Chuang JC, et al.: Lung cancer and indoor air pollution in Xuan Wei, China. Science 666 667 1987, 235:217-220.
- 668 19. Barone-Adesi F, Chapman RS, Silverman DT, He X, Hu W, Vermeulen R, Ning B, Fraumeni 669 JF, Jr., Rothman N, Lan O: Risk of lung cancer associated with domestic use of coal in Xuanwei, China: retrospective cohort study. BMJ 2012, 345:e5414. 670
- 671 20. Chapman RS, He X, Blair AE, Lan Q: Improvement in household stoves and risk of 672 chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. 673 BMJ 2005, 331:1050.
- 674 21. Lin H, Ning B, Li J, Ho SC, Huss A, Vermeulen R, Tian L: Lung cancer mortality among 675 women in Xuan Wei, China: a comparison of spatial clustering detection methods. Asia 676 Pac J Public Health 2015, 27:NP392-401.
- 677 22. Zhang H, Liu C, Li L, Feng X, Wang Q, Li J, Xu S, Wang S, Yang Q, Shen Z, et al: Genomic 678 evidence of lung carcinogenesis associated with coal smoke in Xuanwei area, China. Natl Sci Rev 2021, 8:nwab152. 679
- 680 23. Lan Q, Chapman RS, Schreinemachers DM, Tian L, He X: Household stove improvement 681 and risk of lung cancer in Xuanwei, China. J Natl Cancer Inst 2002, 94:826-835.
- 682 Hosgood HD, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen 24. 683 R, Simko J, Lan Q: Driver mutations among never smoking female lung cancer tissues in 684 China identify unique EGFR and KRAS mutation pattern associated with household 685 coal burning. Respiratory Medicine 2013, 107:1755-1762.
- 25. Wang J, Duan Y, Meng QH, Gong R, Guo C, Zhao Y, Zhang Y: Integrated analysis of DNA 686 687 methylation profiling and gene expression profiling identifies novel markers in lung 688 cancer in Xuanwei, China. PLoS One 2018, 13:e0203155.
- 689 26. Wang X, Li J, Duan Y, Wu H, Xu Q, Zhang Y: Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China. Thorac Cancer 2017, 8:88-96. 690
- Cancer Genome Atlas Research N: Comprehensive molecular profiling of lung 691 27. 692 adenocarcinoma. Nature 2014, 511:543-550.
- Gehring JS, Fischer B, Lawrence M, Huber W: SomaticSignatures: inferring mutational 693 28. 694 signatures from single-nucleotide variants. Bioinformatics 2015, 31:3673-3675.
- 695 Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR: Deciphering 29. signatures of mutational processes operative in human cancer. Cell Rep 2013, 3:246-259. 696
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, 697 30. 698 Bolli N, Borg A, Borresen-Dale AL, et al: Signatures of mutational processes in human 699 cancer. Nature 2013, 500:415-421.
- 700 31. Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, Gomez C, Degasperi A, Harris 701 R, Jackson SP, et al: A Compendium of Mutational Signatures of Environmental Agents. 702 Cell 2019, 177:821-836 e816.

703 32. Petit P, Maitre A, Persoons R, Bicout DJ: Lung cancer risk assessment for workers exposed 704 to polycyclic aromatic hydrocarbons in various industries. Environment International 705 2019, 124:109-120. Widziewicz K, Rogula-Kozlowska W, Majewski G: Lung Cancer Risk Associated with 706 33. 707 Exposure to Benzo(A)Pyrene in Polish Agglomerations, Cities, and Other Areas. 708 International Journal of Environmental Research 2017, 11:685-693. 709 Mangal D, Vudathala D, Park JH, Lee SH, Penning TM, Blair IA: Analysis of 7,8-dihydro-8-34. 710 oxo-2'-deoxyguanosine in cellular DNA during oxidative stress. Chem Res Toxicol 2009, 711 22:788-797. 712 35. Chung JY, Kim JY, Kim YJ, Jung SJ, Park JE, Lee SG, Kim JT, Oh S, Lee CJ, Yoon YD, et al: 713 Cellular defense mechanisms against benzo[a]pyrene in testicular Leydig cells: 714 implications of p53, aryl-hydrocarbon receptor, and cytochrome P450 1A1 status. 715 Endocrinology 2007, 148:6134-6144. 716 Hidaka T, Fujimura T, Aiba S: Arvl Hydrocarbon Receptor Modulates Carcinogenesis and 36. 717 Maintenance of Skin Cancers. Front Med (Lausanne) 2019, 6:194. 718 37. Wiredja DD, Koyuturk M, Chance MR: The KSEA App: a web-based tool for kinase 719 activity inference from quantitative phosphoproteomics. Bioinformatics 2017, 33:3489-720 3491. 721 Casado P, Rodriguez-Prados JC, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S, Cutillas 38. 722 PR: Kinase-substrate enrichment analysis provides insights into the heterogeneity of 723 signaling pathway activation in leukemia cells. Sci Signal 2013, 6:rs6. 724 Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, 39. 725 Chirieac LR, D'Amico TA, et al: Non-Small Cell Lung Cancer, Version 3.2022, NCCN 726 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022, 20:497-530. 727 Janning M, Suptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, 40. 728 Jung A, Kauffmann-Guerrero D, Bonzheim I, et al: Treatment outcome of atypical EGFR 729 mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). 730 Ann Oncol 2022, 33:602-615. 731 41. Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Marten A, Kim ES: Afatinib for the 732 Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 733 Cases. J Thorac Oncol 2020, 15:803-815. 734 42. Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, 735 et al: Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon 736 EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin 737 Oncol 2020, 38:488-495. 738 43. Harada T, Futamura S, Inoue Y, Sawada R, Okuda T, Kagawa K: P2.03-13 Acquired 739 Resistance to Afatinib in Non-Small Cell Lung Cancer with EGFR G719X Mutation. 740 Journal of Thoracic Oncology 2019, 14:S687. 741 44. Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool with confidence 742 assessments and item tracking. Bioinformatics 2010, 26:1572-1573. 743 45. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P: The Molecular 744 Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 2015, 1:417-425. 745 46. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the 746 metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.

747	47.	DeBerardinis RJ, Thompson CB: Cellular metabolism and disease: what do metabolic
748		outliers teach us? Cell 2012, 148:1132-1144.
749	48.	Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer
750		2011, 11: 85-95.
751	49.	Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
752	50.	Pitulescu ME, Schmidt I, Giaimo BD, Antoine T, Berkenfeld F, Ferrante F, Park H, Ehling M,
753		Biljes D, Rocha SF, et al: Dll4 and Notch signalling couples sprouting angiogenesis and
754		artery formation. Nat Cell Biol 2017, 19:915-927.
755	51.	Gridley T: Notch signaling in vascular development and physiology. Development 2007,
756		134: 2709-2718.
757	52.	Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio
758		RN, Menna C, Ding Q, Pagliano O, et al: Fecal microbiota transplant overcomes resistance
759		to anti-PD-1 therapy in melanoma patients. Science 2021, 371:595-602.
760	53.	Dzutsev A, Badger JH, Perez-Chanona E, Roy S, Salcedo R, Smith CK, Trinchieri G:
761		Microbes and Cancer. Annu Rev Immunol 2017, 35:199-228.
762	54.	Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L: Can we harness the
763		microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol 2020,
764		20: 522-528.
765	55.	Kostic AD, Ojesina AI, Pedamallu CS, Jung J, Verhaak RG, Getz G, Meyerson M: PathSeq:
766		software to identify or discover microbes by deep sequencing of human tissue. Nat
767		Biotechnol 2011, 29: 393-396.
768	56.	Lozupone C, Knight R: UniFrac: a new phylogenetic method for comparing microbial
769		communities. Appl Environ Microbiol 2005, 71:8228-8235.
770	57.	Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, Polley EC,
771		Bowman ED, Khan MA, Robles AI, et al: Interaction between the microbiome and TP53 in
772		human lung cancer. Genome Biol 2018, 19:123.
773	58.	Sahni N, Yi S, Taipale M, Fuxman Bass JI, Coulombe-Huntington J, Yang F, Peng J, Weile J,
774		Karras GI, Wang Y, et al: Widespread macromolecular interaction perturbations in
775		human genetic disorders. Cell 2015, 161:647-660.
776	59.	Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, Martin WR, Wang R, Huang J, Hao T, et al:
777		Comprehensive characterization of protein-protein interactions perturbed by disease
778		mutations. Nat Genet 2021, 53: 342-353.
779	60.	Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, et al:
780		ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
781		<i>Sci Rep</i> 2017, 7: 1853.
782	61.	Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M,
783		Sawyers C, Said JW, Koeffler HP: Mutations in the mitotic check point gene, MAD1L1, in
784		human cancers. Oncogene 2001, 20:3301-3305.
785	62.	Yang M, Li B, Liu CJ, Tomchick DR, Machius M, Rizo J, Yu H, Luo X: Insights into mad2
786		regulation in the spindle checkpoint revealed by the crystal structure of the symmetric
787		mad2 dimer. <i>PLoS Biol</i> 2008, 6:e50.
788	63.	Sironi L, Mapelli M, Knapp S, De Antoni A, Jeang KT, Musacchio A: Crystal structure of
789		the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding
790		mechanism for the spindle checkpoint. <i>EMBO J</i> 2002, 21 :2496-2506.

- 791 64. Guo Y, Zhang X, Yang M, Miao X, Shi Y, Yao J, Tan W, Sun T, Zhao D, Yu D, et al: 792 Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes 793 and their impact on susceptibility to lung cancer. J Med Genet 2010, 47:616-622.
- 794 65. Zhong R, Chen X, Chen X, Zhu B, Lou J, Li J, Shen N, Yang Y, Gong Y, Zhu Y, et al: 795 MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk 796 of colorectal cancer. Sci Rep 2015, 5:12202.
- 797 Ferrar T, Chamousset D, De Wever V, Nimick M, Andersen J, Trinkle-Mulcahy L, Moorhead 66. 798 GB: Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate 799 specific, nuclear localized protein phosphatase one alpha (PP1alpha) docking protein. 800 Biol Open 2012, 1:128-139.
- 801 67. Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho 802 CL, et al: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment 803 Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol 2015, 10:793-799. 804
- 805 68. Kunishige M, Ichihara S, Kadota N, Okano Y, Machida H, Hatakeyama N, Naruse K, 806 Shinohara T, Takeuchi E: Non-small cell lung cancer with EGFR (L858R and E709X) and 807 CNNB1 mutations responded to afatinib. Thorac Cancer 2022.
- 808 69. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, 809 Zhou C, et al: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-810 811 Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015, 16:830-838.
- 812 70. Massarelli E, Johnson FM, Erickson HS, Wistuba, II, Papadimitrakopoulou V: Uncommon 813 epidermal growth factor receptor mutations in non-small cell lung cancer and their 814 mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 815 2013, 80:235-241.
- Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung 816 71. 817 DH, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 818 819 **23:**2493-2501.
- 820 72. Floc'h N, Lim S, Bickerton S, Ahmed A, Orme J, Urosevic J, Martin MJ, Cross DAE, Cho 821 BC, Smith PD: Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring 822 the Uncommon EGFR Mutations G719X or L861Q or S768I. Mol Cancer Ther 2020, 823 824 19:2298-2307.
- 73. Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, et al: 825 Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase 826 Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Clin Cancer Res 2018, 827 24:3097-3107. 828
- Wong JYY, Downward GS, Hu W, Portengen L, Seow WJ, Silverman DT, Bassig BA, Zhang 829 74. 830 J, Xu J, Ji BT, et al: Lung cancer risk by geologic coal deposits: A case-control study of 831 female never-smokers from Xuanwei and Fuyuan, China. Int J Cancer 2019, 144:2918-832 2927.
- 833 75. Vermeulen R, Downward GS, Zhang J, Hu W, Portengen L, Bassig BA, Hammond SK, Wong 834 JYY, Li J, Reiss B, et al: Constituents of Household Air Pollution and Risk of Lung

835		Cancer among Never-Smoking Women in Xuanwei and Fuyuan, China. Environ Health
836		Perspect 2019, 127: 97001.
837	76.	Kim C, Chapman RS, Hu W, He X, Hosgood HD, Liu LZ, Lai H, Chen W, Silverman DT,
838		Vermeulen R, et al: Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei,
839		China. Lung Cancer 2014, 84:31-35.
840	77.	Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H,
841		Trajanoski Z: Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype
842		Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 2017,
843		18: 248-262.
844		

Graphical Abstract



847 848

846

Highlights: 849

- We conducted comprehensive multi-omic profiling of air-pollution-850 associated LUAD. 851
- Our study revealed the significant roles of the air pollutant BaP and 852 its induced hot mutation G719X in lung cancer progression. 853
- Multi-omic clustering enabled the identification of personalized 854 therapeutic strategies. 855
- Through mutation-informed interface analysis, we identified novel 856 targets for therapeutic intervention. 857
- 858
- 859





861

Fig 1.| Proteogenomic profiling and mutational signatures in XWLC

a. Four cohort datasets used in this study: XWLC (Lung adenocarcinoma
from non-smoking females in Xuanwei area), CNLC (subset of lung
adenocarcinoma from non-smoking patients in Chinese Human Proteome
Project), TSLC (subset of lung adenocarcinoma from smoking females in

TCGA-LUAD project), TNLC (subset of lung adenocarcinoma from non-867 smoking females in TCGA-LUAD project); b. Age distribution of 868 patients at the time of operation in the four cohorts; c. Distribution of 869 tumor stages across the cohorts; d. Data availability for the XWLC 870 datasets. Each bar represents a sample, with orange bars indicating data 871 availability and gray bars indicating data unavailability; e. Summary of 872 data generated from the XWLC cohort; f-i. Mutational signatures 873 identified in XWLC (f), TSLC (g), TNLC (h), and CNLC (i) cohorts. 874 Cosine similarity analysis of the signatures compared to well-established 875 COMIC signatures (in green) and Kucab et al. signatures (in red). 876 Contribution of signatures in each cohort provided on the right; j. Protein 877 abundance of CYP1A1 in tumor and normal samples within the XWLC 878 cohort; k. Expression levels of the AhR gene in tumor and normal 879 samples within the XWLC cohort; l. Comparison of serum BPDE content 880 in individuals from the Xuanwei area, categorized by young cases and 881 older cases. m. western blotting of EGFR-Y1173, EGFR-Y1068 and 882 EGFR abundance in hiPSC (Control), BaP+S9 treated hiPSC (BaP+S9), 883 and S9 treated hiPSC (S9). Liver S9 is a variety of biological sources 884 represent the post-mitochondrial supernatant fraction from homogenized 885 liver and is known to be a rich source of drug metabolizing enzymes 886 including P-450. Two-tailed Wilcoxon rank sum test used to calculate p-887 values in j-l. 888





890

Fig 2.| Genomic and genetic features in XWLC cohort 891

a. Correlation of genomic mutations among cohorts, determined using the 892 Pearson correlation coefficient; b. Comparison of oncogenic pathways 893 affected by mutations in each cohort; c. Comparison of mutation 894 frequency of four key genes across cohorts; d. Lollipop plot illustrating 895 differences in mutational sites within EGFR (left) and TP53 (right) across 896 XWLC/CNLC, XWLC/TSLC, and XWLC/TNLC pairs; e. Analysis of 897 the percentage of samples with actionable alterations, with a focus on 898 significant variations between XWLC and TSLC cohorts, highlighted by 899 black boxes. 900



902 903

Fig 3.| EGFR-G719X in the XWLC cohort

a. Distribution of different EGFR mutation statuses across the four 904 cohorts; b. Comparison of the fraction of G719X mutations across the 905 four cohorts; c. Detailed information on pG719X (pG719/A/D/C/S) 906 mutations in the XWLC cohort. The number of each mutation type is 907 labeled; d. Distribution of nucleotide pairs surrounding the most common 908 G>T transversion site in the XWLC cohort. The x-axis represents the 909 immediate bases surrounding the mutated base. For BaP, the tallest G>T 910 peak occurs at GpGpG; e-h. Comparison of activation levels of key 911

components in the MAPK pathway across different EGFR mutation statuses in the XWLC cohort; i. Comparison of patient ages across different EGFR mutation statuses in the XWLC cohort; j-k. Presentation of overall survival (OS, j) and progression-free interval (PFI, k) analysis across different EGFR mutation statuses in the TCGA-LUAD cohort; l. Evaluation of kinase activities by KSEA in tumors across different EGFR mutation statuses in the XWLC cohort.



920

921 Fig 4.| Subtyping of XWLC

Integrative classification of samples four tumor into 922 a. ConsensusClusterPlus-derived clusters (MC-I to MC-IV). The heatmap 923 displays the top 50 features, including mRNA transcripts, proteins, and 924 phosphoproteins, for each multi-omic cluster. The features are annotated 925 with representative pathways or genes. If a cluster has fewer than 50 926 features, all features are shown. If no significant GO biological processes 927 are associated with cluster features, all features are displayed; b. 928 Comparison of overall survival between MC-IV and the other three 929 subtypes; c-d. Protein abundance comparison of CYCP1A1 (c) and AHR 930

- 931 (d) across subtypes; e. Protein-level correlation between CYCP1A1 and
- 932 EGFR; f. Protein-level comparison of EGFR across subtypes; g.
- 933 Evaluation of kinase activities by KSEA in tumors across subtypes in the
- 934 XWLC cohort.







a. Relative expression of epithelial-mesenchymal transition (EMT) markers across subtypes; b. EMT scores across subtypes using a gene set derived from MsigDB (M5930); c-d. Protein abundance comparison of FN1 (c) and β -Catenin (d) across subtypes; e. Protein and phosphoprotein

levels of key cell cycle kinases across subtypes; f. Expression of mRNA 942 and protein levels of glycolysis-associated enzymes; g. mRNA expression 943 of VEGFA across subtypes; h. Phosphoprotein abundance of VEGFR1 944 across subtypes; i. Angiogenesis score across subtypes using a gene set 945 derived from MsigDB (Systematic name M5944); j. Expression 946 comparison of key regulators of the Notch pathway across subtypes; k. 947 Metabolism-associated hallmarks across subtypes. Gene sets for oxidative 948 phosphorylation, peroxisome, adipogenesis, fatty acid metabolism, and 949 xenobiotic metabolism were derived from MsigDB hallmark gene sets; 1. 950 Expression of PD-1 signaling-associated genes across subtypes. PD-1 951 signaling-associated genes were derived from MsigDB (Systematic name 952 M18810); m. Immune cell infiltration across subtypes. Gene sets for 953 each immune cell type were derived from a previous study[77]; n. 954 Expression of anti-tumor/pro-tumor lymphocyte receptors and ligands 955 across subtypes. The two-tailed Wilcoxon rank sum test was used to 956 calculate p-values in panels b, c, d, g, h, i, and m. 957





959

Fig **Microbiota** composition and radiomic **6.** features 960 across subtypes. 961

a. Abundance of bacterial sequencing reads per million (RPM) across 962 tumor molecular subtypes and adjacent normal tissues. Significance was 963 determined using a paired two-sided Wilcoxon rank sum test; b. Principal 964 coordinates analysis (PCoA) plot of mRNA data for XWLC samples 965 shows significant variation between tumor and adjacent normal samples 966

along the first axis of variation, and variation between MC-IV subtypes 967 and the other three tumor subtypes along the second axis; c. Heatmap of 968 bacterial species' abundance highly expressed in the MC-IV subtype 969 compared to the other three subtypes in the XWLC cohort. Bacterial 970 species labeled green prefer an acidic living environment; d. Eight 971 features showing significant differences between MC-II and the other 972 three subtypes. The Wilcoxon rank sum test was used to calculate the p-973 values; e. A receiver operating characteristic (ROC) curve was used to 974 evaluate the performance of the radiomic signature in distinguishing MC-975 II from the other three subtypes; f. Confusion matrix allows visualization 976 of the performance of the algorithm in separating MC-II from other 977 subtypes. 978





980 981

Fig.7|Identification of novel targets in XWLC

a. Flow chart showing the integration of mutation-informed PPI analysis, 982 molecular dynamic simulation and experiment validation to identify 983 novel targets; b. Network visualization of XWLC oncoPPIs. Edge 984 thickness represents the number of missense mutations at the protein-985 protein interaction (PPI) interface, while node size indicates connectivity; 986

c. MAD1-MAD2 interaction model and the p.Arg558His mutation at the 987 interface (left). The complex model was generated using Zdock protein 988 docking simulation. The right distribution showing root-mean-squared 989 deviation (RMSD) during a 20 ns molecular dynamics simulation of 990 MAD1 wild type vs. MAD1 p.Arg558His in the complex; d. Model 991 showing the p.His550Gln alteration within the TPRN-PPP1CA complex 992 (left). The right distribution showing root-mean-squared deviation 993 (RMSD) during a 20 ns molecular dynamics simulation for TPRN wild 994 type vs. TPRN p.His550Gln (H550Q) in the complex; e. Survival analysis 995 of TPRN mutation group and unaltered group derived from cbioportal 996 using TCGA-LUAD cohort (https://www.cbioportal.org/); f. CCK8 assay 997 for TPRN-MT, TPRN-WT, and CK cell lines in A549 cells which was 998 transfected by mutant TPRN, wild-type and empty vector, respectively. g. 999 Transwell assay for TPRN-MT, TPRN-WT, and CK after 24h and 36h in 1000 A549 cells. Magnification was set to 40x; h.Bar chart showing the 1001 statistical results of transwell assay; i. Cell colon assay for TPRN-MT, 1002 TPRN-WT and CK in A549 and H1299 cell line. The two-tailed 1003 Wilcoxon rank sum test was used to calculate p-values in f and h. 1004 *.p<0.05; **,p<0.01; ***, p<0.001; 1005